aTyr Pharma (NASDAQ:ATYR) Downgraded by Wall Street Zen to “Sell”

aTyr Pharma (NASDAQ:ATYR) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company upped their target price on aTyr Pharma from $17.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, June 20th. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a report on Wednesday, June 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.20.

aTyr Pharma Stock Performance

NASDAQ ATYR opened at $5.30 on Friday. The company has a market cap of $471.70 million, a P/E ratio of -6.62 and a beta of 0.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.79 and a current ratio of 7.79. The business’s 50 day moving average price is $5.34 and its 200-day moving average price is $4.12. aTyr Pharma has a fifty-two week low of $1.67 and a fifty-two week high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). Sell-side analysts predict that aTyr Pharma will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in aTyr Pharma by 467.8% during the 4th quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company’s stock valued at $646,000 after buying an additional 147,092 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in aTyr Pharma during the 4th quarter valued at about $881,000. Bank of America Corp DE acquired a new position in aTyr Pharma during the 4th quarter valued at about $330,000. Jane Street Group LLC acquired a new position in shares of aTyr Pharma in the fourth quarter valued at about $720,000. Finally, Millennium Management LLC acquired a new position in shares of aTyr Pharma in the fourth quarter valued at about $1,332,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.